Akari Therapeutics PLC (AKTX)
1.525
+0.04
(+3.04%)
USD |
NASDAQ |
May 17, 16:00
1.525
0.00 (0.00%)
After-Hours: 20:00
Akari Therapeutics Research and Development Expense (Quarterly)
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2022 | 2.851M |
| March 31, 2022 | 2.140M |
| December 31, 2021 | 3.851M |
| September 30, 2021 | -0.4302M |
| June 30, 2021 | 2.183M |
| March 31, 2021 | 3.529M |
| December 31, 2020 | 4.660M |
| September 30, 2020 | -1.592M |
| June 30, 2020 | 3.020M |
| March 31, 2020 | 2.732M |
| December 31, 2019 | 5.701M |
| September 30, 2019 | 1.763M |
| June 30, 2019 | 3.593M |
| March 31, 2019 | -2.318M |
| December 31, 2018 | 2.362M |
| September 30, 2018 | 3.304M |
| June 30, 2018 | 5.121M |
| Date | Value |
|---|---|
| March 31, 2018 | 1.008M |
| December 31, 2017 | 7.118M |
| September 30, 2017 | 6.382M |
| June 30, 2017 | 3.782M |
| March 31, 2017 | 6.003M |
| December 31, 2016 | 6.570M |
| September 30, 2016 | 3.794M |
| June 30, 2016 | 5.443M |
| March 31, 2016 | 1.500M |
| December 31, 2015 | 1.930M |
| September 30, 2015 | 1.313M |
| June 30, 2015 | 1.001M |
| March 31, 2015 | 1.555M |
| December 31, 2014 | 1.076M |
| September 30, 2014 | 0.1626M |
| June 30, 2014 | 1.54M |
| March 31, 2014 | 0.80M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
-1.592M
Minimum
Sep 2020
5.701M
Maximum
Dec 2019
2.616M
Average
2.851M
Median
Jun 2022
Research and Development Expense (Quarterly) Benchmarks
| DBV Technologies SA | 21.40M |
| Cellectis SA | 25.53M |
| Adaptimmune Therapeutics PLC | 35.21M |
| Biodexa Pharmaceuticals Plc | -- |
| NuCana PLC | 8.519M |